. 2011 May;18(5):736–742. doi: 10.1128/CVI.00542-10

Table 2.

Characteristics of Neisseria meningitidis capsular group B strains used to measure serum bactericidal activity

Strain^a	fHbp		Serotype/serosubtype	Clonal complex	LOS immunotype^d	fHbp ID prevalence (%) in^e:
Strain^a	ID^b	Modular group^c	Serotype/serosubtype	Clonal complex	LOS immunotype^d	USA	UK	France
H44/76	1	I	B:15:P1.7,16	32	L3,7,9	30	4	20
NM008	4	I	B:4:P1.4	41/44	L3,7,9	14	24	7
GB200	13	I	B:NT:P1.22,9	269	L1	5	10	2
NZ98/254	14	I	B:4:P1.7-2,4	41/44	L3,7,9	5	7	23
NM117	15	IV	B:21:P1.9	269	L1	0.3	22	6
GB101	15	IV	B:NT:P1.19,15	269	L1,8

H44/76 and its derivatives were used to prepare the NOMV vaccines. It also expressed an fHbp with the same amino acid sequence as that of the recombinant fHbp vaccine.

fHbp identification number assigned in the fHbp database (http://pubmlst.org/neisseria/fHbp/).

fHbp modular group as described by Beernink and Granoff (2) and Pajon et al. (33).

Determined by whole-cell ELISA and anti-LOS monoclonal antibodies 2-1-L8, 9-2-L379, 17-1-L1 and 14-1-L-10.

The five fHbp variants accounted for 54, 67, and 58% of all group B isolates from cases in the United States, the United Kingdom, and France, respectively (28, 33).